Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress

Contributed by: PR Newswire

Tags

SOBI-Gamifant-study

More Like This

US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)

New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference

Sobi to present new data at ASH 2023 Annual Meeting

Sobi to present new data at EAHAD 2024

Sobi's strength in haematology to be showcased at ASH 2024

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome